---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-041663"
form_type: "8-K"
ticker: "ROIV"
cik: "0001635088"
company_name: "Roivant Sciences Ltd."
filed_at: "2024-09-23T23:59:59+00:00"
generated_at: "2026-05-31T02:27:17.955071+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Roivant sells Dermavant to Organon for up to $1.2B in cash plus royalties

## Summary
- Total consideration up to ~$1.2B: $175M at closing, $75M milestone on FDA approval for atopic dermatitis, up to $950M in net sales milestones.
- Tiered royalties: low-to-mid single-digit % on net sales up to $1B, 30% on net sales above $1B; all paid pro rata to Dermavant equity holders.
- Roivant owns ~87% of Dermavant; merger expected to close Q4 2024, subject to HSR and antitrust conditions.
- Organon will assume Dermavant's existing revenue interest purchase and funding agreements at closing.
- Merger approved by Dermavant and Roivant boards and by shareholders holding at least 75% voting rights.

## SEC filing metadata
- accession: 0001140361-24-041663
- form_type: 8-K
- ticker: ROIV
- cik: 0001635088
- company_name: Roivant Sciences Ltd.
- filed_at: 2024-09-23T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1635088/000114036124041663/0001140361-24-041663-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1635088/000114036124041663/ny20036156x1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-041663
- JSON: https://secwatch.observer/filing/0001140361-24-041663.json
- Plain text: https://secwatch.observer/filing/0001140361-24-041663.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.